Keyphrases
Acute Myeloid Leukemia
100%
Venetoclax
36%
Myelodysplastic Syndrome
31%
Newly Diagnosed
24%
Overall Survival
23%
Myeloid Neoplasms
20%
Intensive Chemotherapy
18%
Chronic Myeloid Leukemia
17%
Complete Remission
16%
Tumor Protein p53 (TP53)
15%
Bone Marrow
15%
Neoplasms
15%
Relapsed or Refractory Acute Myeloid Leukemia
14%
Hypomethylating Agents
14%
Minimal Residual Disease
13%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
13%
Leukemia Patients
12%
Chronic Lymphocytic Leukemia
12%
Nucleophosmin 1 (NPM1)
11%
Myeloproliferative Neoplasms
11%
Isocitrate Dehydrogenase 1 (IDH1)
11%
Relapsed or Refractory
10%
Median Overall Survival
10%
Immunophenotypic Profile
10%
FLT3 Inhibitor
9%
Clinical Outcomes
9%
Older Patients
8%
TP53 mutation
8%
Myeloid Malignancies
8%
Leukemia
8%
Myeloid Cell leukemia-1 (Mcl-1)
7%
Azacitidine
7%
Clonal Hematopoiesis
7%
Acute Lymphoblastic Leukemia
7%
Hematopoietic Stem Cells
7%
Relapse-free Survival
7%
FMS-like Tyrosine Kinase 3 (FLT3)
7%
Remission
7%
International Consortium
7%
Myelodysplastic Neoplasms
6%
Complex Karyotype
6%
Prognostic Impact
6%
Diffuse Large B-cell Lymphoma (DLBCL)
6%
Phase II Trial
6%
Risk Stratification
6%
Overall Response Rate
6%
Clonal Evolution
6%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
6%
Cytarabine
6%
Ponatinib
6%
Medicine and Dentistry
Acute Myeloid Leukemia
96%
Neoplasm
57%
Myelodysplastic Syndrome
39%
Venetoclax
30%
Overall Survival
29%
Diseases
28%
Acute Lymphoblastic Leukemia
15%
Chronic Myelomonocytic Leukemia
14%
Morphology
14%
Myeloproliferative Neoplasm
14%
Acute Myelogenous Leukemia
12%
NPM1
12%
Hematopoiesis
12%
Leukemia
12%
Minimal Residual Disease
12%
Hypomethylating Agent
10%
Gene Mutation
10%
Diagnosis
10%
Karyotype
9%
T Cell
9%
Malignant Neoplasm
9%
Next Generation Sequencing
9%
Diffuse Large B-Cell Lymphoma
9%
B-Cell Chronic Lymphocytic Leukemia
9%
Rituximab
8%
Hematologic Malignancy
7%
Gene Frequency
7%
Recurrence Free Survival
7%
Myeloid Malignancy
7%
B Cell
6%
Chronic Myelogenous Leukemia
6%
Cytarabine
6%
Prognostic Factor
6%
B-Cell Lymphoma
6%
Event Free Survival
6%
Ponatinib
6%
Hematopathology
5%
Azacitidine
5%
Epstein Barr Virus
5%
Allogeneic Stem Cell Transplantation
5%
Eosinophilia
5%
COVID-19
5%
Richter's Transformation
5%
Nodular Lymphocyte Predominant Hodgkin's Lymphoma
5%
Natural Killer Cell
5%
Optical Genome Mapping
5%